18,507 Shares in Liquidia Co. (NASDAQ:LQDA) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new stake in Liquidia Co. (NASDAQ:LQDA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 18,507 shares of the company's stock, valued at approximately $218,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Barclays PLC lifted its stake in shares of Liquidia by 265.0% during the third quarter. Barclays PLC now owns 99,984 shares of the company's stock valued at $999,000 after buying an additional 72,591 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Liquidia by 855.3% during the third quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company's stock valued at $2,354,000 after buying an additional 210,753 shares during the period. DMC Group LLC lifted its stake in shares of Liquidia by 17.4% during the fourth quarter. DMC Group LLC now owns 16,302 shares of the company's stock valued at $192,000 after buying an additional 2,419 shares during the period. Catalina Capital Group LLC lifted its stake in shares of Liquidia by 6.5% during the fourth quarter. Catalina Capital Group LLC now owns 18,307 shares of the company's stock valued at $215,000 after buying an additional 1,125 shares during the period. Finally, Rhumbline Advisers increased its position in Liquidia by 3.5% during the fourth quarter. Rhumbline Advisers now owns 80,652 shares of the company's stock worth $948,000 after purchasing an additional 2,741 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company's stock.

Liquidia Stock Performance

Shares of LQDA stock traded up $0.65 on Thursday, hitting $19.30. The stock had a trading volume of 1,833,968 shares, compared to its average volume of 1,020,154. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of -11.84 and a beta of 0.24. The stock's 50 day moving average is $14.46 and its 200-day moving average is $13.32. Liquidia Co. has a 52-week low of $8.26 and a 52-week high of $19.41.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The firm had revenue of $3.12 million during the quarter, compared to analysts' expectations of $3.23 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. Equities analysts expect that Liquidia Co. will post -1.51 earnings per share for the current year.

Insider Activity

In other Liquidia news, insider Jason Adair sold 1,856 shares of the stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $25,185.92. Following the transaction, the insider now directly owns 184,304 shares in the company, valued at $2,501,005.28. This represents a 1.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel Russell Schundler sold 5,964 shares of the firm's stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $80,931.48. Following the completion of the transaction, the general counsel now owns 570,301 shares in the company, valued at approximately $7,738,984.57. The trade was a 1.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 33,138 shares of company stock worth $450,233. 30.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Scotiabank reaffirmed an "outperform" rating on shares of Liquidia in a research report on Monday, May 5th. Raymond James increased their price objective on shares of Liquidia from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a research report on Friday, May 9th. Needham & Company LLC reissued a "buy" rating and issued a $25.00 price objective on shares of Liquidia in a research report on Monday. Finally, HC Wainwright reissued a "buy" rating and issued a $29.00 price objective on shares of Liquidia in a research report on Monday. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $27.13.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).